AGM
PDLI

Alpine Global Management’s PDL BioPharma, Inc. PDLI Stock Holding History

Alpine Global Management’s Portfolio PDLI Stock Details PDLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-10,300
Closed -$79K – 659
2014
Q4 		$79K Buy
+10,300
New +$81.5K 0.01% 519

Other funds holding PDLI

First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
AAM
Advisors Asset Management Monument, Colorado $6.01B AUM 24.74% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GAM
Gotham Asset Management New York $32.7B AUM 27.65% 1-Year Est. Return

Alpine Global Management's PDLI Position: Q1 2015 in Review

Alpine Global Management sold out of PDL BioPharma, Inc. (PDLI) in Q1 2015, closing a stake of 10,300 shares — an estimated $79K sold.

Alpine Global Management first reported a position in PDLI in Q4 2014 and held it in 1 quarter. The position peaked at $79K in Q4 2014. 215 funds tracked by Wall St. Rank hold PDLI as of Q1 2015.

  • Alpine Global Management reported no remaining PDL BioPharma, Inc. position as of Q1 2015 after selling out during the quarter.
  • Alpine Global Management sold 10,300 PDL BioPharma, Inc. shares in Q1 2015, an estimated $79K.
  • Alpine Global Management first reported a position in PDL BioPharma, Inc. in Q4 2014 and held it in 1 quarter.
  • Alpine Global Management's PDL BioPharma, Inc. position peaked at $79K in Q4 2014.
  • 215 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q1 2015.

Based on Alpine Global Management's 13F filing for Q1 2015, filed 5 May 2015.